These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

999 related articles for article (PubMed ID: 26874581)

  • 1. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
    Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenovirus Vector Harboring the HBcAg and Tripeptidyl Peptidase II Genes Induces Potent Cellular Immune Responses In Vivo.
    Tan Q; Ma S; Hu J; Chen X; Yu Y; Tang Z; Zang G
    Cell Physiol Biochem; 2017; 41(2):423-438. PubMed ID: 28214886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-based vaccination with lentiviral vectors encoding ubiquitinated hepatitis B core antigen enhances hepatitis B virus-specific immune responses in vivo.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Tang Z; Zang G
    Acta Biochim Biophys Sin (Shanghai); 2015 Nov; 47(11):870-9. PubMed ID: 26373843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances HBV-specific humoral and CTL immune responses in vivo.
    Song L; Zhuo M; Tang Y; Chen X; Tang Z; Zang G
    Int Immunopharmacol; 2014 Nov; 23(1):1-7. PubMed ID: 25135878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice.
    Zhuo M; Song L; Tang Y; Dai S; Chen X; Yu Y; Zang G; Tang Z
    Mol Med Rep; 2015 Sep; 12(3):3591-3598. PubMed ID: 26004262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of CTLs induced by DCs loaded with ubiquitinated hepatitis B virus core antigen.
    Chen JH; Yu YS; Chen XH; Liu HH; Zang GQ; Tang ZH
    World J Gastroenterol; 2012 Mar; 18(12):1319-27. PubMed ID: 22493545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Engineered DC-Targeting Lentivector Induces Robust T Cell Responses and Inhibits HBV Replication in HBV Transgenic Mice via Upregulating T Cell Autophagy.
    Ma S; Chen X; Tan Q; Dai S; Li D; Wu S; Yu Y; Zang G; Tang Z
    Cell Physiol Biochem; 2018; 48(3):1041-1059. PubMed ID: 30041239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
    Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
    Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice.
    Chen X; Lai J; Pan Q; Tang Z; Yu Y; Zang G
    Vaccine; 2010 May; 28(23):3913-9. PubMed ID: 20394723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with lentiviral vector‑modified dendritic cells encoding ubiquitinated hepatitis B core antigen promotes Th1 differentiation and antiviral immunity by enhancing p38 MAPK and JNK activation in HBV transgenic mice.
    Dai S; Chen X; Yu Y; Zang G; Tang Z
    Mol Med Rep; 2018 Nov; 18(5):4691-4699. PubMed ID: 30221736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
    Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
    J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal route favors the induction of CD4
    Bourgine M; Crabe S; Lobaina Y; Guillen G; Aguilar JC; Michel ML
    Antiviral Res; 2018 May; 153():23-32. PubMed ID: 29510155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
    Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
    Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
    Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
    J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8+ T-cell responses in HLA-A2.1/Kb transgenic mice.
    Zhang Y; Li S; Shan M; Pan X; Zhuang K; He L; Gould K; Tien P
    Immunology; 2007 May; 121(1):105-12. PubMed ID: 17244158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fusion protein of tapasin and hepatitis B core antigen 18‑27 enhances T helper cell type 1/2 cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members 1/3 in hepatitis B virus transgenic mice.
    Tang Y; Chen X; Zhang Y; Tang Z; Zhuo M; Li D; Wang P; Zang G; Yu Y
    Mol Med Rep; 2014 Apr; 9(4):1171-8. PubMed ID: 24535102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBcAg18-27 epitope fused to HIV-Tat 49-57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice.
    Wang S; Han Q; Zhang N; Chen J; Liu Z; Zhang G; Li Z
    Immunol Lett; 2010 Jan; 127(2):143-9. PubMed ID: 19883689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo.
    Chen X; Tang Y; Zhang Y; Zhuo M; Tang Z; Yu Y; Zang G
    Lab Invest; 2014 May; 94(5):478-90. PubMed ID: 24614195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.